Alexion to Acquire Portola for ~$1.41B

Shots: Shots:

• Alexion to acquire all shares of Portola’s common stock at $18/ share in cash with a premium of 132%. Alexion will be acquiring cash currently on Portola’s balance sheet, net of debt of ~$215M that will become due upon closing. The actual amounts will be determined following the closure of the transaction
• The transaction is expected to be closed in Q3’20. The acquisition will expand Alexion’s hematology, neurology and critical care commercial portfolio with the addition of Portola’s Andexxa/ Ondexxya
• Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya in EU, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the effects rivaroxaban and apixaban in severe and uncontrolled bleeding

Click here ­to­ read full press release/ article | Ref: Alexion | Image: Portola